No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
QGEN240517C35000
- 9.60
- +1.80+23.08%
15min DelayClose May 10 15:55 ET
9.60High9.60Low
9.60Open7.80Pre Close1 Volume39 Open Interest35.00Strike Price960.00Turnover178.32%IV1.58%PremiumMay 17, 2024Expiry Date8.61Intrinsic Value100Multiplier5DDays to Expiry0.99Time Value100Contract SizeAmericanOptions Type0.8715Delta0.0224Gamma4.69Leverage Ratio-0.1885Theta0.0042Rho4.09Eff Leverage0.0110Vega
Intraday
- 5D
- 1D
News
Express News | NYSE Order Imbalance 92847.0 Shares on Buy Side
Express News | NYSE Order Imbalance 58834.0 Shares on Buy Side
QIAGEN Partners With FBI to Develop Digital PCR Assay for QIAcuity for Use in Forensics
Collaboration aims to create novel digital PCR assay to improve successful results in DNA analysis from human samples for use in forensics and human identification // DNA quantification enables law en
Express News | NYSE Order Imbalance 64100.0 Shares on Sell Side
Will Earnings Cheer Continue This Week? All Eyes On Disney, Palantir, Robinhood While Reddit Gears Up For Debut Quarterly Report
Earnings reports and a dovish stance from the Federal Reserve lifted stocks last week. Major indices reacted positively, particularly to earnings from high-profile companies that hold significant weig
QIAGEN Enhances Bioinformatics Workflows With New Secondary Analysis Solution for Oncology and Inherited Disease Applications
QCI Secondary Analysis a cloud-based software directly integrated with QCI Interpret, enabling high-throughput secondary analysis of clinical next-generation sequencing data // New software advances p
Comments
Qiagen's high P/E ratio is worrisome due to its poor earnings forecast. Despite the high P/E, investors retain their shares, but this earnings growth rate may eventually impact the share price. The high P/E and future earnings predictions pose a substantial risk to shareholders and potential investors.
There's Reason For Concern Over Qiagen N.V.'s (NYSE:QGEN) PriceQiagen's performance is strong due to strategic profit reinvestment, leading to significant earnings growth. Its respectable ROE contributes to a net income increase. Yet, forecasts anticipate a slowdown in future earnings growth.
2
Here are the top gap ups and downs for the stocks with a market cap above $5 billion after the previous market closed (gaps range from large to small):
Gap Ups
1. $SolarEdge Technologies(SEDG.US$ - up 7.31%
2. $Kohl's Corp(KSS.US$ - up 4.46%
3. $DuPont(DD.US$ - up 4.38%
4. $Welltower Inc(WELL.US$ - up 4.02%
5. $CNH Industrial(CNHI.US$ - up 3.18%
6. $Planet Fitness(PLNT.US$ - up 3.46%
7. $Qiagen NV(QGEN.US$ - up 2.35%
8. $Taiwan Semiconductor(TSM.US$ - up 2.05...
Gap Ups
1. $SolarEdge Technologies(SEDG.US$ - up 7.31%
2. $Kohl's Corp(KSS.US$ - up 4.46%
3. $DuPont(DD.US$ - up 4.38%
4. $Welltower Inc(WELL.US$ - up 4.02%
5. $CNH Industrial(CNHI.US$ - up 3.18%
6. $Planet Fitness(PLNT.US$ - up 3.46%
7. $Qiagen NV(QGEN.US$ - up 2.35%
8. $Taiwan Semiconductor(TSM.US$ - up 2.05...
+17
18
Gapping up
$Qiagen NV(QGEN.US$ +3.4% (the biotech company raised its full-year outlook, pointing to particular strength in its non-Covid product portfolio.)
$Lordstown Motors(RIDE.US$ +14.6% (contract manufacturer Foxconn will invest up to $170 million in the electric vehicle maker and become its largest shareholder.)
$DuPont(DD.US$ +3.7% (the industrial materials maker beat top and bottom line estimates for the third quarter. Du...
$Qiagen NV(QGEN.US$ +3.4% (the biotech company raised its full-year outlook, pointing to particular strength in its non-Covid product portfolio.)
$Lordstown Motors(RIDE.US$ +14.6% (contract manufacturer Foxconn will invest up to $170 million in the electric vehicle maker and become its largest shareholder.)
$DuPont(DD.US$ +3.7% (the industrial materials maker beat top and bottom line estimates for the third quarter. Du...
9
1
Read more